Day: March 14, 2023

Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

Written by Customer Service on March 14, 2023. Posted in Earnings Releases And Operating Results.

– Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients – – Plan to initiate the CHORD™ trial in the First Half of 2023 – – Presented key non-clinical data at the 46th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate – BOSTON, March 14, 2023 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “I am...

INNOVATE Corp. Announces Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 14, 2023. Posted in Earnings Releases And Operating Results.

– Infrastructure: DBM Global finishes year strong; achieves 37% revenue growth for 2022 –– Life Sciences: MediBeacon completed enrollment of both U.S. and China Pivotal Studies –– Spectrum: Broadcasting added contracts with three major networks and launched new programming – – Company meets Continued Listing Standards from NYSE – NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) — INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the fourth quarter and fiscal year ended December 31, 2022. Financial Summary(in millions, except per share amounts) Three Months Ended December 31, Years Ended December 31, 2022 2021 Increase / (Decrease) 2022 2021 Increase / (Decrease)Revenue $ 409.3 $ 394.8 3.7 % $ 1,637.3 $ 1,205.2 35.9 %Net...

Lulus Reports Fourth Quarter 2022 Results and Record Fiscal Year Net Revenue

Written by Customer Service on March 14, 2023. Posted in Earnings Releases And Operating Results.

Record-Breaking Full Year 2022 Net Revenue of $440 million, up 17% from 2021 Full Year Net Income of $3.7 million, up 82% from 2021 Grew Active Customers, up 17% from 2021 CHICO, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU) today reported financial results for the fourth quarter and full year ended January 1, 2023. Crystal Landsem, CEO of Lulus, said: “We’re proud to have completed our first full year as a public company on solid ground with a clean balance sheet free of high-cost term debt, which enabled us to continue investing in the business. We saw year-over-year growth in repeat customers during the fourth quarter, as well as healthy year-over-year growth in Active Customers, which shows that our brand continues to resonate with our customers. Like...

Snap One Reports Fiscal Fourth Quarter and Full Year 2022 Results

Written by Customer Service on March 14, 2023. Posted in Earnings Releases And Operating Results.

Full Year 2022 Net Sales of $1.124 Billion Notable Achievements Across Product Suite and Growth Verticals Build on Best-In-Class Integrator Partner Experience Company Introduces Financial Outlook for Fiscal 2023 CHARLOTTE, N.C., March 14, 2023 (GLOBE NEWSWIRE) — Snap One Holdings Corp. (Nasdaq: SNPO) (“Snap One,” the “Company,” “we,” or “our”), a provider of smart living products, services, and software to professional integrators, reported financial results for the fiscal fourth quarter and full year ended December 30, 2022. Fiscal Full Year 2022 and Recent Operational HighlightsContinued investment to deliver industry-leading integrator partner experienceAwarded 17 2022 CE Pro Quest for Quality Awards out of 22 identified sub-categories Ranked a top-three brand 40 times across 62 identified product sub-categories in the 2022...

Yield10 Bioscience Announces Fourth Quarter and Full Year 2022 Financial Results

Written by Customer Service on March 14, 2023. Posted in Earnings Releases And Operating Results.

-Executing strategy to build supply chain alliances for the production of low-carbonintensity Camelina feedstock oil for the biofuels market-Advancing development of herbicide tolerant Camelina varieties-Accelerating development of omega-3 Camelina -Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., March 14, 2023 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2022. “Yield10 is building a diverse Camelina products business based on our differentiated technology capabilities in this promising crop,” said Oliver Peoples, Ph.D., President and Chief Executive Officer...

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Written by Customer Service on March 14, 2023. Posted in Earnings Releases And Operating Results.

Data from ongoing Phase 2 trial evaluating pomotrelvir (formerly known as PBI-0451) for the treatment of COVID-19 expected in the coming weeks Cash to fund operations for the next twelve months CARLSBAD, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing pomotrelvir as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment of COVID-19, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. “We are greatly encouraged by the progress made in our ongoing Phase 2 study evaluating pomotrelvir for the treatment of COVID-19, and we continue to believe in its potential to fulfill the unmet demand for a stand-alone, oral antiviral treatment that...

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Written by Customer Service on March 14, 2023. Posted in Earnings Releases And Operating Results.

NEWARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) — Rafael Holdings, Inc. (NYSE: RFL), today reported its second quarter fiscal 2023 financial results for the three months and six months ended January 31, 2023. “Our strong balance sheet allows us to continue to fund our pipeline assets and explore selective strategic business development opportunities, which potentially could improve the lives of patients and generate value for our shareholders,” said Bill Conkling, CEO of Rafael Holdings. Rafael Holdings, Inc. Second Quarter Fiscal Year 2023 Financial Results As of January 31, 2023, we had cash, cash equivalents and marketable securities of $88.9 million. For the three months ended January 31, 2023, we incurred a net loss from continuing operations of $3.3 million, or $0.13 per share. For the same period in the prior year, we incurred...

Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes

Written by Customer Service on March 14, 2023. Posted in Public Companies.

Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edemaand Announces Board Changes Trial has now enrolled more than two-thirds of total subjectsBuilds upon Interim Analysis Outcome in DecemberTop-line Data Anticipated in Q4 2023 Leuven, BELGIUM, Boston, MA, US – March 14, 2023 – 9:00 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has enrolled more than two-thirds of the planned total enrollment in its KALAHARI Phase 2, Part B clinical trial (KALAHARI trial). The KALAHARI trial is evaluating Oxurion’s novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for patients with...

Link Reservations, Inc. (LRSV) Announces Acquisition of Global Enterprises & Logistics, Inc.

Written by Customer Service on March 14, 2023. Posted in Mergers And Acquisitions.

MIAMI, March 14, 2023 (GLOBE NEWSWIRE) — Link Reservations Inc. (OTC PINK: LRSV) (the “Company”) is pleased to announce today, that further to the Letter of Intent (“LOI”) dated June 6th, 2022 with Global Enterprises and Logistics, Inc. (”Global”), as disclosed in the Supplemental Disclosure filed with OTC Markets Group March 9th, 2023, the Company has successfully completed the acquisition of Global Enterprises & Logistics, Inc., as a wholly owned subsidiary of the Company through a Share Exchange Agreement (“SEA”) dated March 3rd, 2023. Global Enterprises and Logistics, Inc. is a provider of refrigerated freight forwarding and individualized logistics for a wide spectrum of clients in the wholesale and retail food industry, including the hospitality industry, both of which rely on the timely delivery of regular and recurring...

Nokia Corporation: Repurchase of own shares on 14.03.2023

Written by Customer Service on March 14, 2023. Posted in Public Companies.

Nokia CorporationStock Exchange Release14 March 2023 at 21:00 EET Nokia Corporation: Repurchase of own shares on 14.03.2023 Espoo, Finland – On 14 March 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 293,931 4.38CEUX 18,168 4.41AQEU 2,500 4.41TQEX 2,401 4.41Total 317,000 4.38* Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU)...

Day: March 14, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice